Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$6,897 Mln
P/E Ratio
23.06
P/B Ratio
6.34
Industry P/E
--
Debt to Equity
0
ROE
0.33 %
ROCE
24.78 %
Div. Yield
0 %
Book Value
15.11
EPS
4.34
CFO
$936.70 Mln
EBITDA
$716.70 Mln
Net Profit
$474.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| 13.26 | 0.22 | 10.64 | 64.13 | 18.90 | 50.44 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| 43.86 | 21.66 | 76.39 | 114.16 | -34.23 | 31.05 | -23.36 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable... ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Address: 201 Burlington Road, Bedford, MA, United States, 01730 Read more
CEO & Director
Mr. Brian A. Markison
CEO & Director
Mr. Brian A. Markison
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lantheus Holdings Inc (LNTH) stood at $ 1,980 Mln as on 31-Dec-24
The share price of Lantheus Holdings Inc (LNTH) is $101.32 (NASDAQ) as of 17-Apr-2025 16:06 EDT. Lantheus Holdings Inc (LNTH) has given a return of 18.9% in the last 3 years.
Lantheus Holdings Inc (LNTH) has a market capitalisation of $ 6,897 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Lantheus Holdings Inc (LNTH) is 23.06 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lantheus Holdings Inc (LNTH) and enter the required number of quantities and click on buy to purchase the shares of Lantheus Holdings Inc (LNTH).
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Address: 201 Burlington Road, Bedford, MA, United States, 01730
The CEO & director of Mr. Brian A. Markison. is Lantheus Holdings Inc (LNTH), and CFO & Sr. VP is Mr. Brian A. Markison.
There is no promoter pledging in Lantheus Holdings Inc (LNTH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Lantheus Holdings Inc. (LNTH) | Ratios |
|---|---|
|
Return on equity(%)
|
32.82
|
|
Operating margin(%)
|
29.38
|
|
Net Margin(%)
|
20.37
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lantheus Holdings Inc (LNTH) was $0 Mln.
$0.80
(
